Orbotech (ORBK) Stock Higher, Barclays Raises Price Target

NEW YORK (TheStreet) -- Shares of Orbotech  (ORBK) are up by 1.81% to $28.40 late Wednesday afternoon, as Barclays raised its price target on the stock to $32 from $29 this morning.

The firm maintained its "overweight" rating after analysts hosted meetings last week with the Isreal-based electronic solutions producer's Asher Levy, CEO, and Amichai Steimberg, President and COO.

"The general tone of the meetings was positive with management discussing all of the various technology transitions driving growth and the relative stability of the business now that one-third of sales comes from each segment," Barclays analysts said in an investor note.

The transition to and growing market of organic light-emitting diodes (OLEDs), used in digital screens such as televisions, was the "main topic of discussion," according to Barclays.

Separately, TheStreet Ratings rated Orbotech as a "buy" with a score of A.

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

This is based on the convergence of positive investment measures. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels.

Although no company is perfect, currently TheStreet Ratings does not see any significant weaknesses which are likely to detract from the generally positive outlook.

You can view the full analysis from the report here: ORBK

More from Markets

Nvidia Shares Tank as Analysts Cut Price Targets

Nvidia Shares Tank as Analysts Cut Price Targets

Oil, Energy Stocks, Recover After Volatile Week

Oil, Energy Stocks, Recover After Volatile Week

Flashback Friday: Nvidia Is the Ultimate Chip and Dip

Flashback Friday: Nvidia Is the Ultimate Chip and Dip

Pfizer Plans Price Hikes for 41 Drugs Next Year

Pfizer Plans Price Hikes for 41 Drugs Next Year

Dow Ends Higher on Dovish Trump Tariff Comments; Nasdaq Falls

Dow Ends Higher on Dovish Trump Tariff Comments; Nasdaq Falls